Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $7.0500 (-6.13%) ($7.0500 - $7.0950) on Wed. Feb. 10, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.85% (three month average) | RSI | 38 | Latest Price | $7.0500(-6.13%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.4% a day on average for past five trading days. | Weekly Trend | AUTL declines -3.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) SKYY(13%) XBI(13%) BNDX(12%) LIT(12%) ARKG(11%) | Factors Impacting AUTL price | AUTL will decline at least -2.425% in a week (0% probabilities). USO(-7%) TBT(-7%) IGOV(-7%) UNG(-5%) VIXM(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.425% (StdDev 4.85%) | Hourly BBV | -0.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $8.21 | 5 Day Moving Average | $7.92(-10.98%) | 10 Day Moving Average | $7.72(-8.68%) | 20 Day Moving Average | $8.21(-14.13%) | To recent high | -40.7% | To recent low | 0% | Market Cap | $368m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |